Walking certain number of steps daily reduces cancer risk, Oxford study finds
A new study led by Oxford researchers reveals that casual walking and other light-intensity activities are enough to lower cancer incidence.
The number of steps was found to be more important than the pace of the walk, they found.
Just 4 Minutes Of Intense Daily Activity Could Slash Cancer Risk Among 'Non-exercisers,' Study Finds
Those who walked 7,000 steps per day had an 11% lower cancer risk compared to those taking 5,000 steps per day, and the risk was 16% lower for those taking 9,000 steps per day, according to a press release from the Oxford Centre for Early Cancer Detection at the University of Oxford.
Even shopping and performing household chores have been shown to reduce cancer risk.
Read On The Fox News App
Overall, those who had the highest total amount of daily physical activity were 26% less likely to develop cancer compared to those with the lowest amount, after adjusting for lifestyle factors, body mass index (BMI) and other health conditions.
The study, which was recently published in the British Journal of Sports Medicine, analyzed activity tracker data for 85,394 people in the UK Biobank averaging 63 years of age.
Cancer Deaths And Tax Rates Linked In Surprising New Study: Here's How
They then compared that data with future cancer diagnoses in 2,633 participants over a nearly six-year period.
While previous studies have used self-reported exercise to determine reduced cancer risk, this one used "more precise data" based on wearable activity trackers.
"Our research highlights the importance of all forms of movement," senior study author Aiden Doherty, professor of biomedical informatics at Oxford Population Health, said in the release.
"Whether it's increasing daily steps, engaging in light activity or incorporating moderate-to-vigorous exercise, any level of physical activity appears to contribute to lower cancer risk."
"Our findings support and enhance current national and international physical activity guidelines, showing that people who often engage in simple low-intensity activities, such as walking, have a lower risk of developing cancer."
Click Here To Sign Up For Our Health Newsletter
Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News senior medical analyst, pointed out that cancer is linked to inflammation, which is linked to sedentary behavior.
"All kinds of activity, including walking, increases metabolic function and decreases inflammation," Siegel, who was not involved in the study, told Fox News Digital.
"The results of this study are not surprising and are in keeping with previous and ongoing research."
For more Health articles, visit www.foxnews.com/health
In addition to Oxford Health researchers, experts from the National Institutes of Health and National Cancer Institute participated in the study.
Funding was provided by the National Institutes of Health's Intramural Research Program and the National Institutes of Health's Oxford Cambridge Scholars Program.Original article source: Walking certain number of steps daily reduces cancer risk, Oxford study finds
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
a minute ago
- Bloomberg
Roche Suffers Setback as Lung Drug Gets Mixed Result in Trial
Roche Holding AG 's experimental drug for a deadly lung condition got mixed results in trials, a setback as the company seeks to accelerate the development of new treatments. The late-stage trials for astegolimab — the medicine being developed to treat chronic obstructive pulmonary disease, or COPD — offered contrasting results, according to a statement on Monday.
Yahoo
29 minutes ago
- Yahoo
GP honoured for 35 years of helping the homeless
A GP from Leicester who has worked to improve the health of homeless people since 1990 has been given an honorary doctorate. Dr Nigel Hewett accepted an honorary Doctorate of Science award from the University of Leicester at a ceremony at De Montfort Hall on Thursday. In 2000, he set up the Leicester Homeless Primary Healthcare Service - which became Inclusion Healthcare - to provide services for homeless and other marginalised people. He was awarded an OBE in 2006 for services to homeless people and in 2009 he launched University College London Hospital's Pathway homelessness team. A lifelong Leicester resident, Dr Hewett said he was "delighted and humbled" by the honour. "Leicester has an outstanding primary health care service for people experiencing homelessness and asylum seekers," he said. "We should be proud to be national leaders in this field and this humbling award is a recognition of multidisciplinary team work over the decades." In 2010, he was a founder member of the Faculty for Homeless and Inclusion Health and became medical director of Pathway – a charity formed to support the faculty and improve the healthcare of homeless people and other excluded groups. Dr Hewett told the BBC: "I've always felt drawn to people on the margins of society and people who have had the most to gain from health care. "There's a thing called the inverse care law which suggests that the more you need medical care the harder it is to get it and homeless people are at the extreme end of that spectrum of deprivation." Homeless 'feel invisible' Dr Hewett said he saw one of his former patients while visiting the University of Sheffield. The patient had problems with heroin, but with the help of methadone went on a long-term detox and is now signing on for a PhD after completing a degree in criminology. "There's always a way back," Dr Hewett said. "You have to hang on to the wins in this work, because for most people they have age of death in the early 40s and it's often a very sad story." He added that homeless people often "talk of feeling invisible" and said "the rest of us can help, I think, by just making eye contact and saying hello". Follow BBC Leicester on Facebook, on X, or on Instagram. Send your story ideas to eastmidsnews@ or via WhatsApp on 0808 100 2210. More on this story Kasabian frontman receives honorary degree Council to keep new flats for homeless families Council to buy student flats to house homeless Related internet links University of Leicester
Yahoo
an hour ago
- Yahoo
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease
The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeks The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified Analysis of the ALIENTO and ARNASA data will be discussed with regulatory authorities and shared at an upcoming medical meeting Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The pivotal phase IIb ALIENTO study met its primary endpoint and showed that astegolimab reduced the annualised exacerbation rate (AER) by a statistically significant 15.4% at 52 weeks, when given every two weeks. However, the phase III ARNASA study did not meet its primary endpoint of a statistically significant reduction in the AER, demonstrating a numerical 14.5% reduction, at 52 weeks when astegolimab was given every two weeks. The results were generally consistent across secondary endpoints in both studies. The total number of exacerbations was lower than prospectively anticipated in both trials. The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified. "While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for managing this debilitating and complex disease," said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. "This was the first set of studies in an 'all-comers' COPD population, and we will discuss these data with regulatory authorities to evaluate next steps for astegolimab.' Detailed results from ALIENTO and ARNASA will be shared at an upcoming medical meeting. About the ALIENTO and ARNASA studies1,2Astegolimab is an investigational, fully human anti-ST2 monoclonal antibody designed to bind with high affinity to the ST2 receptor, thereby blocking the signalling of IL-33.3 The astegolimab COPD pivotal programme consists of two registrational studies, the phase IIb ALIENTO (NCT05037929) and phase III ARNASA (NCT05595642) studies. Both ALIENTO and ARNASA are double-blinded, placebo-controlled, multicentre studies that evaluate the efficacy and safety of astegolimab administered every two or every four weeks in patients with COPD on top of standard of care maintenance therapy. Patients in the studies included former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations. The primary analysis is based on the initial phase of the study, which consisted of 1,301 patients for ALIENTO and 1,375 patients for ARNASA. The primary endpoint is the reduction in the annualised rate of moderate and severe COPD exacerbations (AER) over the 52-week treatment period. AER is the total number of exacerbations (a sudden worsening in airway function and respiratory symptoms) occurring over the relevant treatment period, divided by the total number of patient years. Standard of care maintenance therapy for both studies was one of the following combinations – inhaled corticosteroid (ICS) plus long-acting beta-agonist (LABA); long-acting muscarinic antagonist (LAMA) plus LABA; ICS plus LAMA plus LABA. About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (ARNASA). [Internet; cited March 2025]. Available from: [2] A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease. [Internet; cited March 2025]. Available from: Kelsen SG, Agache O, Soong W, Israel E, Chupp GL, Cheung DS, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. Journal of Allergy and Clinical Immunology. 2021 Sep;148(3):790–8. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Roche Investor Relations Dr Bruno EschliPhone: +41 61 68-75284e-mail: Dr Sabine BorngräberPhone: +41 61 68-88027e-mail: Dr Birgit MasjostPhone: +41 61 68-84814e-mail: Relations North America Loren KalmPhone: +1 650 225 3217e-mail: Media Investor Release Astegolimab ALIENTO ARNASA EnglishSign in to access your portfolio
